The Proteomics of Positron Emission Tomography

Annals of Neurology

Volumn 55, Issue 3, 2004, Pages 303-305

  Jagust, William ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICYANO 2 [6 (DIMETHYLAMINO) 2 NAPHTHALENYL]PROPENE FLUORODEOXYGLUCOSE F 18; ACETYLCHOLINESTERASE; ALPHA SYNUCLEIN; AMYLOID PROTEIN; CARBON 11; FLUORODEOXYGLUCOSE F 18; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; PRION PROTEIN; RADIOLIGAND; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; BLOOD FLOW; BRAIN REGION; CEREBELLUM; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG BINDING; DRUG UPTAKE; EDITORIAL; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; ISOTOPE LABELING; MATHEMATICAL MODEL; METABOLIC DISORDER; MOUSE; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENIC MOUSE; TREATMENT INDICATION; VALIDATION PROCESS; VASCULAR AMYLOIDOSIS; WHITE MATTER;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; HUMANS; PROTEOMICS; RADIOPHARMACEUTICALS; THIAZOLES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1442304945     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20053     Document Type: Editorial

References (14)

1. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
2. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.
3. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699.
4. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-1809.
5. Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000;48:194-200.
6. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000;48:391-395.
7. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
8. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 2003;100:12462-12467.
9. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′ -methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092.
10. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
11. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligoomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
12. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
13. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21: RC189.
14. Bresjanac M, Smid LM, Vovko TD, et al. Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl] ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 2003;23:8029-8033.